DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts have given DENTSPLY SIRONA Inc. an average rating of "Hold", with one sell recommendation, eleven hold recommendations, and two buy recommendations.
• The company's average 12-month price objective is set at $18.00, but different brokers have varying targets, ranging from $13.00 to $25.00.
• DENTSPLY SIRONA recently reported a quarterly EPS of $0.52, exceeding analysts' expectations, despite a 4.9% decline in year-over-year revenue.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) have received an average rating of "Hold" from the fourteen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $18.00.

XRAY has been the subject of a number of recent research reports. UBS Group lowered their price objective on DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wall Street Zen raised DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research note on Friday, September 26th. Evercore ISI decreased their price target on DENTSPLY SIRONA from $17.00 to $13.00 and set an "in-line" rating for the company in a research note on Wednesday. Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a research note on Friday, September 26th. Finally, Wells Fargo & Company decreased their price target on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating for the company in a research note on Friday, August 8th.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $11.83 on Friday. The company has a market cap of $2.36 billion, a P/E ratio of -2.50, a PEG ratio of 0.74 and a beta of 0.96. The stock has a fifty day moving average price of $13.50 and a 200 day moving average price of $14.60. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11. DENTSPLY SIRONA has a 12 month low of $11.69 and a 12 month high of $24.93.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The firm had revenue of $936.00 million during the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The firm's revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.49 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. On average, research analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 10th. Stockholders of record on Friday, September 26th were paid a $0.16 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $0.64 annualized dividend and a dividend yield of 5.4%. DENTSPLY SIRONA's dividend payout ratio is presently -13.50%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of DENTSPLY SIRONA by 2.8% in the first quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock worth $309,864,000 after purchasing an additional 557,329 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of DENTSPLY SIRONA by 11.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock valued at $208,590,000 after buying an additional 1,412,517 shares during the period. AQR Capital Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock valued at $211,470,000 after buying an additional 6,970,086 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of DENTSPLY SIRONA by 4.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier's stock valued at $180,445,000 after buying an additional 538,531 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of DENTSPLY SIRONA by 8.0% in the second quarter. Lazard Asset Management LLC now owns 10,107,657 shares of the medical instruments supplier's stock valued at $160,508,000 after buying an additional 745,421 shares during the period. Institutional investors own 95.70% of the company's stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.